



Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

SHARE

TWEET

LINKEDIN

PIN IT

EMAIL

PRINT

[Home](#) | [Back to Search Results](#)

Product Details for NDA 202155

[Expand all](#)

ELIQUIS (APIXABAN)	
2.5MG	Marketing Status: Prescription
<div><div>Active Ingredient: APIXABAN</div><div>Proprietary Name: ELIQUIS</div><div>Dosage Form; Route of Administration: TABLET; ORAL</div><div>Strength: 2.5MG</div><div>Reference Listed Drug: Yes</div><div>Reference Standard: No</div><div>TE Code:</div><div>Application Number: N202155</div><div>Product Number: 001</div><div>Approval Date: Dec 28, 2012</div></div>	

Applicant Holder Full Name: BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
Marketing Status: Prescription
[Patent and Exclusivity Information](#)

ELIQUIS (APIXABAN)
5MG
Marketing Status: Prescription

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).
Language Assistance Available: [Español](#) | [繁體中文](#) | [Tiếng Việt](#) | [Tagalog](#) | [Русский](#) | [Kreyòl Ayisyen](#) | [Français](#) | [Polski](#) | [Português](#) | [Italiano](#) | [Deutsch](#) | [日本語](#) | [English](#)

- Accessibility
- FDA Basics
- No FEAR Act
- Nondiscrimination
- Careers
- FOIA
- Site Map
- Website Policies

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
1-888-INFO-FDA (1-888-463-6332)

Contact FDA



[FDA Archive](#)